AstraZeneca has stopped its Phase III Enthuse Study 15 of zibotentan monotherapy in patients with non-metastatic, castration-resistant prostate cancer after a review found that the treatment was unlikely to meet its primary efficacy endpoints.

The review, conducted by the Independent Data Monitoring Committee, indicated that zibotentan monotherapy was unlikely to benefit patients with this type of cancer.

Study 15 is part of the Enthuse clinical trial programme, which consists of three clinical studies designed to evaluate the efficacy and safety of zibotentan in extending survival in men with castration-resistant prostate cancer.

Enthuse Study 14 has already been concluded, leaving only Study 33 in the programme.

Study 33 will evaluate zibotentan plus chemotherapy, compared to chemotherapy alone, in men whose disease has metastasised and who have been prescribed treatment with chemotherapy.